EVALUATION OF HERCEPTIN-177LU FOR THERAPY OF MICE BREAST CANCER

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

RASANEH SAMIRA; YAVARI KAMAL

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Breast Diseases Year:2014 | Volume:7 | Issue:3 Page(s): 7-11

Download Full-Text

Persian Verion

View:

941

Download:

Cites:

Information Journal Paper

Title

EVALUATION OF HERCEPTIN-177LU FOR THERAPY OF MICE BREAST CANCER

Author(s)

RASANEH SAMIRA | YAVARI KAMAL | Issue Writer Certificate

Keywords

BREAST CANCERQ2

THERAPYQ2

HERCEPTINQ3

LABELINGQ3

177LUTETIUMQ3

RADIO IMMUNOTHERAPYQ3

Abstract

Background: HERCEPTIN is a monoclonal antibody that is used in treating BREAST CANCER. In this study, HERCEPTIN is labeled with lutetium-177 and after performing all the quality control tests the therapeutic efficiency was evaluated in the mice bearing breast tumor.Methods: HERCEPTIN was labeled with 177Lu via DOTA. The quality control tests included LABELING efficiency, stability in buffer and blood serum, immunoreactivity and stability in mice were performed and therapeutic efficiency was evaluated in mice bearing breast tumor.Results: LABELING efficiency more than 90%, stability in buffer and blood serum up to 7 days 85% and 75% respectively, immunoreactivity 86% suggested that 177Lu-Herceptin could be used as a RADIO IMMUNOTHERAPY agent. The results of THERAPY in mice showed that the injection of complex (300 m Ci) could limit the tumor growth up to 15 days.Conclusion: By the good results of animal study, 177Lu-Herceptin could be considered as a new radiopharmaceutical agent for use in RADIO IMMUNOTHERAPY of BREAST CANCER in humans that needs more investigation.

Cites

No record.

References

Cite

APA: Copy

RASANEH, SAMIRA, & YAVARI, KAMAL. (2014). EVALUATION OF HERCEPTIN-177LU FOR THERAPY OF MICE BREAST CANCER. IRANIAN QUARTERLY JOURNAL OF BREAST DISEASE, 7(3), 7-11. SID. https://sid.ir/paper/144608/en

Vancouver: Copy

RASANEH SAMIRA, YAVARI KAMAL. EVALUATION OF HERCEPTIN-177LU FOR THERAPY OF MICE BREAST CANCER. IRANIAN QUARTERLY JOURNAL OF BREAST DISEASE[Internet]. 2014;7(3):7-11. Available from: https://sid.ir/paper/144608/en

IEEE: Copy

SAMIRA RASANEH, and KAMAL YAVARI, “EVALUATION OF HERCEPTIN-177LU FOR THERAPY OF MICE BREAST CANCER,” IRANIAN QUARTERLY JOURNAL OF BREAST DISEASE, vol. 7, no. 3, pp. 7–11, 2014, [Online]. Available: https://sid.ir/paper/144608/en

Related Journal Papers